XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
  Columnists
  Editorials
  Discussions
  Surveys
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Nov 17th, 2006 - 22:35:04

Opinion Channel
subscribe to Opinion newsletter

Medical News : Opinion

   DISCUSS   |   EMAIL   |   PRINT
Statement from NHLBI on the Findings of the Women’s Health Study
Mar 29, 2005, 00:36, Reviewed by: Dr.


The Women’s Health Study found that aspirin did not prevent first heart attacks or death from cardiovascular causes in women. Low-dose aspirin (100 mg on alternate days) lowered the incidence of a first major cardiovascular event (nonfatal heart attack, non-fatal stroke, or death from cardiovascular causes) by 9 percent. This was not statistically significant.


 
The Women’s Health Study is the first large clinical trial to study the use of low-dose aspirin to prevent heart attack and stroke in women. The 10-year randomized, double-blind, placebo-controlled study was conducted among nearly 40,000 healthy women age 45 and older. Although studies have shown that low-dose aspirin reduces the risk of a first heart attack in men, there have been few such studies in women. The study was supported by the National Institutes of Health’s National Heart, Lung, and Blood Institute and the National Cancer Institute.

The Women’s Health Study found that aspirin did not prevent first heart attacks or death from cardiovascular causes in women. Low-dose aspirin (100 mg on alternate days) lowered the incidence of a first major cardiovascular event (nonfatal heart attack, non-fatal stroke, or death from cardiovascular causes) by 9 percent. This was not statistically significant. Stroke was 17 percent lower in the aspirin group, a statistically significant difference. The findings of the study will be presented at the American College of Cardiology’s (ACC) annual meeting in Orlando, FL and also published online in The New England Journal of Medicine March 7, 2005 and in print in the March 31 issue.

The greatest benefit appeared to be in women 65 and older. In this sub-group, low-dose aspirin reduced the risk of major cardiovascular events by 26 percent. However, the benefits of low-dose aspirin therapy must be weighed against the risk of an increased chance of internal bleeding, a well-known side effect of aspirin use.

The bottom line is that many women, especially those 65 and older, may benefit from taking low-dose aspirin every other day to prevent stroke. But it is important for women to weigh the risk and benefits of taking aspirin and to consult with their doctor. Above all, women, like men, should adopt the well-proven approaches that reduce the risk of heart disease – eating for heart health, getting regular physical activity, maintaining a healthy weight, not smoking, and controlling high cholesterol, high blood pressure, and diabetes.

The Women’s Health Study also assessed the benefits of vitamin E supplementation (600 IU every other day). These findings, also presented at ACC, indicate there was no evidence of cardiovascular benefit or increased risk from taking a vitamin E supplement. Analyses of the effect of vitamin E and aspirin on cancer are under way.
 

- National Heart, Lung, and Blood Institute (NHLBI)
 

NHLBI website

 
Subscribe to Opinion Newsletter
E-mail Address:

 

NHLBI is part of the National Institutes of Health (NIH), the Federal Government's primary agency for biomedical and behavioral research. NIH is a component of the U.S. Department of Health and Human Services. Additional information about women and heart disease is available at the NHLBI website,(www.nhlbi.nih.gov).

Related Opinion News

The role of activated Protein C in severe sepsis
Why Kenneth Clarke is unfit to be Tory leader - BMJ
Sports utility vehicles and older pedestrians
Call for moratorium on ‘virgin conception’ research
Funding the public health response to terrorism
Cosmetic surgery normal part of everyday life for British women
First European heart failure awareness survey reveals massive public lack of awareness
HIV testing should be Routine
Public has a Moral Obligation to take part in Scientific Research
Professionalism and Professional Ethics in Medicine


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us